Nifedipine in the management of preterm labor: a systematic review and metaanalysis
American Journal of Obstetrics and Gynecology, ISSN: 0002-9378, Vol: 204, Issue: 2, Page: 134.e1-134.e20
2011
- 130Citations
- 277Captures
- 4Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations130
- Citation Indexes122
- 122
- CrossRef57
- Policy Citations6
- Policy Citation6
- Clinical Citations1
- PubMed Guidelines1
- Patent Family Citations1
- Patent Families1
- Captures277
- Readers277
- 277
- Mentions4
- References3
- Wikipedia3
- Blog Mentions1
- Blog1
Most Recent Blog
ATISOBAN
ATOSIBAN cas 90779-69-4 WeightAverage: 994.19 Monoisotopic: 993.441208989 Chemical FormulaC43H67N11O12S2 (2S)-5-amino-2-{[(2S)-1-[(4R,7S,10S,13S,16R)-13-[(2S)-butan-2-yl]-7-(carbamoylmethyl)-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)pentanamide * Oxytocin, 1-(3-mer
Article Description
To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labor. A systematic review and metaanalysis of randomized controlled trials. Twenty-six trials (2179 women) were included. Nifedipine was associated with a significant reduction in the risk of delivery within 7 days of initiation of treatment and before 34 weeks' gestation, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, neonatal jaundice, and admission to the neonatal intensive care unit when compared with β 2 -adrenergic-receptor agonists. There was no difference between nifedipine and magnesium sulfate in tocolytic efficacy. Nifedipine was associated with significantly fewer maternal adverse events than β 2 -adrenergic-receptor agonists and magnesium sulfate. Maintenance nifedipine tocolysis was ineffective in prolonging gestation or improving neonatal outcomes when compared with placebo or no treatment. Nifedipine is superior to β 2 -adrenergic-receptor agonists and magnesium sulfate for tocolysis in women with preterm labor.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0002937810023185; http://dx.doi.org/10.1016/j.ajog.2010.11.038; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79551490993&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/21284967; https://linkinghub.elsevier.com/retrieve/pii/S0002937810023185; http://www.ajog.org/article/S0002-9378(10)02318-5/abstract; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.ajog.org%2Farticle%2FS0002-9378%2810%2902318-5%2Fabstract&rc=0&code=ymob-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.ajog.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa8druUXgUK07ZzBYJxv%2526MAID%253DiZE0tNKwvEdEqu5vDcNyNg%25253D%25253D%2526SERVER%253DWZ6myaEXBLGliB%25252BRW%25252F74SA%25253D%25253D%2526ORIGIN%253D893392996%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.ajog.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa8druUXgUK07ZzBYJxv%2526MAID%253DiZE0tNKwvEdEqu5vDcNyNg%25253D%25253D%2526SERVER%253DWZ6myaEXBLGliB%25252BRW%25252F74SA%25253D%25253D%2526ORIGIN%253D893392996%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.ajog.org%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaa8druUXgUK07ZzBYJxv%26MAID%3DiZE0tNKwvEdEqu5vDcNyNg%253D%253D%26SERVER%3DWZ6myaEXBLGliB%252BRW%252F74SA%253D%253D%26ORIGIN%3D893392996%26RD%3DRD&acw=&utt=
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know